Table of Contents Author Guidelines Submit a Manuscript
Multiple Sclerosis International
Volume 2019, Article ID 7151685, 19 pages
https://doi.org/10.1155/2019/7151685
Review Article

Enduring Clinical Value of Copaxone® (Glatiramer Acetate) in Multiple Sclerosis after 20 Years of Use

Director, Clinical Research; Consultants in Neurology, Multiple Sclerosis Center, Northbrook, IL, USA

Correspondence should be addressed to Daniel R. Wynn; moc.liamg@dmnnywd

Received 9 January 2018; Revised 29 June 2018; Accepted 29 November 2018; Published 15 January 2019

Academic Editor: Bruno Brochet

Copyright © 2019 Daniel R. Wynn. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. H. L. Zwibel and J. Smrtka, “Improving quality of life in multiple sclerosis: An unmet need,” The American Journal of Managed Care, vol. 17, pp. S139–S145, 2011. View at Google Scholar · View at Scopus
  2. L. H. Hua and J. A. Cohen, “Considerations in the development of generic disease therapies for multiple sclerosis,” Neurology: Clinical Practice, vol. 6, no. 4, pp. 369–376, 2016. View at Publisher · View at Google Scholar · View at Scopus
  3. B. Weinstock-Guttman, K. V. Nair, J. L. Glajch, T. C. Ganguly, and D. Kantor, “Two decades of glatiramer acetate: From initial discovery to the current development of generics,” Journal of the Neurological Sciences, vol. 376, pp. 255–259, 2017. View at Publisher · View at Google Scholar · View at Scopus
  4. G. Borchard and D. J. A. Crommelin, “Equivalence of glatiramer acetate products: Challenges in assessing pharmaceutical equivalence and critical clinical performance attributes,” Expert Opinion on Drug Delivery, vol. 15, no. 3, pp. 247–259, 2018. View at Publisher · View at Google Scholar · View at Scopus
  5. O. Abramsky, D. Teitelbaum, and R. Arnon, “Effect of a synthetic polypeptide (COP 1) on patients with multiple sclerosis and with acute disseminated encephalomyelitis. Preliminary report,” Journal of the Neurological Sciences, vol. 31, no. 3, pp. 433–438, 1977. View at Publisher · View at Google Scholar · View at Scopus
  6. M. B. Bornstein, A. I. Miller, D. Teitelbaum, R. Arnon, and M. Sela, “Multiple sclerosis: Trial of a synthetic polypeptide,” Annals of Neurology, vol. 11, no. 3, pp. 317–319, 1982. View at Publisher · View at Google Scholar · View at Scopus
  7. G. Comi, M. P. Amato, A. Bertolotto et al., “The heritage of glatiramer acetate and its use in multiple sclerosis,” Multiple Sclerosis and Demyelinating Disorders, vol. 1, no. 1, article 6, 2016. View at Publisher · View at Google Scholar
  8. IQVIA Health National Prescription Audit, March 2017.
  9. K. A. Hanson, N. Agashivala, K. W. Wyrwich, K. Raimundo, E. Kim, and D. W. Brandes, “Treatment selection and experience in multiple sclerosis: Survey of neurologists,” Patient Preference and Adherence, vol. 8, pp. 415–422, 2014. View at Google Scholar · View at Scopus
  10. Sandoz, “GLATOPA™ (glatiramer acetate injection), for subcutaneous use,” 2015, https://www.glatopa.com/cs/www.glatopa.com/assets/PDF/Glatopa-Package-Insert-06-2015.pdf.
  11. J. Cohen, A. Belova, K. Selmaj et al., “Equivalence of generic glatiramer acetate in multiple sclerosis: A randomized clinical trial,” JAMA Neurology, vol. 72, no. 12, pp. 1433–1441, 2015. View at Publisher · View at Google Scholar · View at Scopus
  12. Mylan, “Glatiramer acetate, glatiramer acetate injection, solution,” 2018, https://www.glatirameracetate.com.
  13. A. M. Lavery, L. H. Verhey, and A. T. Waldman, “Outcome measures in relapsing-remitting multiple sclerosis: Capturing disability and disease progression in clinical trials,” Multiple Sclerosis International, vol. 2014, Article ID 262350, 2014. View at Publisher · View at Google Scholar
  14. B. F. Popescu and C. F. Lucchinetti, “Meningeal and cortical grey matter pathology in multiple sclerosis,” BMC Neurology, vol. 12, article 11, 2012. View at Publisher · View at Google Scholar · View at Scopus
  15. National Multiple Sclerosis Society, “The history of MS,” 2016, https://www.nationalmssociety.org/NationalMSSociety/media/MSNationalFiles/Brochures/Brochure-History-of-Multiple-Sclerosis.pdf.
  16. O. Fernández, V. Fernández, T. Arbizu et al., “Characteristics of multiple sclerosis at onset and delay of diagnosis and treatment in Spain (the Novo study),” Journal of Neurology, vol. 257, no. 9, pp. 1500–1507, 2010. View at Publisher · View at Google Scholar · View at Scopus
  17. C. H. Polman, S. C. Reingold, B. Banwell et al., “Diagnostic criteria for multiple sclerosis: 2010 revisions to the McDonald criteria,” Annals of Neurology, vol. 69, no. 2, pp. 292–302, 2011. View at Publisher · View at Google Scholar · View at Scopus
  18. A. J. Thompson, B. L. Banwell, F. Barkhof et al., “Diagnosis of multiple sclerosis: 2017 revisions of the McDonald criteria,” The Lancet Neurology, vol. 17, no. 2, pp. 162–173, 2018. View at Publisher · View at Google Scholar · View at Scopus
  19. H.-C. von Büdingen, A. Palanichamy, K. Lehmann-Horn, B. A. Michel, and S. S. Zamvil, “Update on the autoimmune pathology of multiple sclerosis: B-cells as disease-drivers and therapeutic targets,” European Neurology, vol. 73, no. 3-4, pp. 238–246, 2015. View at Publisher · View at Google Scholar · View at Scopus
  20. S. L. Hauser, E. Waubant, D. L. Arnold et al., “B-cell depletion with rituximab in relapsing-remitting multiple sclerosis,” The New England Journal of Medicine, vol. 358, no. 7, pp. 676–688, 2008. View at Publisher · View at Google Scholar · View at Scopus
  21. A. Bar-Or, P. A. Calabresi, D. Arnold et al., “Rituximab in relapsing-remitting multiple sclerosis: A 72-week, open-label, phase I trial,” Annals of Neurology, vol. 63, no. 3, pp. 395–400, 2008. View at Publisher · View at Google Scholar · View at Scopus
  22. A. Rae-Grant, G. S. Day, R. A. Marrie et al., “Practice guideline recommendations summary: Disease-modifying therapies for adults with multiple sclerosis: Report of the Guideline Development, Dissemination, and Implementation Subcommittee of the American Academy of Neurology,” Neurology, vol. 90, no. 17, pp. 777–788, 2018. View at Publisher · View at Google Scholar
  23. G. Giovannoni, H. Butzkueven, S. Dhib-Jalbut et al., “Brain health: Time matters in multiple sclerosis,” Multiple Sclerosis and Related Disorders, vol. 9, pp. S5–S48, 2016. View at Publisher · View at Google Scholar · View at Scopus
  24. G. Fenu, L. Lorefice, F. Frau, G. C. Coghe, M. G. Marrosu, and E. Cocco, “Induction and escalation therapies in multiple sclerosis,” Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry, vol. 14, no. 1, pp. 26–34, 2015. View at Publisher · View at Google Scholar · View at Scopus
  25. I. Lazibat, B. Nevajda, G. Grahovac, and V. V. Brinar, “Should MS be treated by escalation or induction therapy?” Collegium Antropologicum, vol. 38, pp. 385–393, 2014. View at Google Scholar
  26. J. R. Corboy, B. G. Weinshenker, and D. M. Wingerchuk, “Comment on 2018 American Academy of Neurology guidelines on disease-modifying therapies in MS,” Neurology, vol. 90, no. 24, pp. 1106–1112, 2018. View at Publisher · View at Google Scholar
  27. H. Hegen, G. Bsteh, and T. Berger, “‘No evidence of disease activity’—is it an appropriate surrogate in multiple sclerosis?” European Journal of Neurology, vol. 25, no. 9, 1107-e101, 2018. View at Publisher · View at Google Scholar
  28. S. D. Newsome, P. J. Aliotta, J. Bainbridge et al., “A framework of care in multiple sclerosis, part 2: Symptomatic care and beyond,” International Journal of MS Care, vol. 19, no. 1, pp. 42–56, 2017. View at Publisher · View at Google Scholar · View at Scopus
  29. F. Khan, L. Turner-Stokes, L. Ng, and T. Kilpatrick, “Multidisciplinary rehabilitation for adults with multiple sclerosis,” Cochrane Database of Systematic Reviews, vol. 2, Article ID CD006036, 2007. View at Google Scholar
  30. A. Toosy, O. Ciccarelli, and A. Thompson, “Symptomatic treatment and management of multiple sclerosis,” Handbook of Clinical Neurology, vol. 122, pp. 513–562, 2014. View at Google Scholar
  31. M. J. Barry and S. Edgman-Levitan, “Shared decision making—pinnacle of patient-centered care,” The New England Journal of Medicine, vol. 366, no. 9, pp. 780-781, 2012. View at Publisher · View at Google Scholar · View at Scopus
  32. M. Tintoré, M. Alexander, K. Costello et al., “The state of multiple sclerosis: Current insight into the patient/health care provider relationship, treatment challenges, and satisfaction,” Patient Preference and Adherence, vol. 11, pp. 33–45, 2016. View at Publisher · View at Google Scholar · View at Scopus
  33. H. Wekerle, “Nature, nurture, and microbes: The development of multiple sclerosis,” Acta Neurologica Scandinavica, vol. 136, pp. 22–25, 2017. View at Publisher · View at Google Scholar · View at Scopus
  34. P. K. Coyle, “Pharmacogenetic biomarkers to predict treatment response in multiple sclerosis: Current and future perspectives,” Multiple Sclerosis International, vol. 2017, Article ID 6198530, 2017. View at Publisher · View at Google Scholar
  35. N. J. Scolding, M. Pasquini, S. C. Reingold, and J. A. Cohen, “Cell-based therapeutic strategies for multiple sclerosis,” Brain, vol. 140, no. 11, pp. 2776–2796, 2017. View at Publisher · View at Google Scholar · View at Scopus
  36. L. Kappos, A. Bar-Or, B. A. C. Cree et al., “Siponimod versus placebo in secondary progressive multiple sclerosis (EXPAND): A double-blind, randomised, phase 3 study,” Lancet, vol. 391, pp. 1263–1273, 2018. View at Publisher · View at Google Scholar
  37. Teva Pharmaceuticals USA, Inc., “COPAXONE (glatiramer acetate) solution for subcutaneous injection,” https://www.accessdata.fda.gov/drugsatfda_docs/label/2009/020622s057lbl.pdf.
  38. M. B. Bornstein, A. Miller, S. Slagle et al., “A pilot trial of cop 1 in exacerbating-remitting multiple sclerosis,” The New England Journal of Medicine, vol. 317, no. 7, pp. 408–414, 1987. View at Publisher · View at Google Scholar · View at Scopus
  39. K. P. Johnson, B. R. Brooks, J. A. Cohen et al., “Copolymer 1 reduces relapse rate and improves disability in relapsing-remitting multiple sclerosis: Results of a phase III multicenter, double-blind, placebo-controlled trial. The Copolymer 1 Multiple Sclerosis Study Group,” Neurology, vol. 45, no. 7, pp. 1268–1276, 1995. View at Publisher · View at Google Scholar · View at Scopus
  40. G. Comi, M. Filippi, and J. S. Wolinsky, “European/Canadian multicenter, double-blind, randomized, placebo-controlled study of the effects of glatiramer acetate on magnetic resonance imaging-measured disease activity and burden in patients with relapsing multiple sclerosis. European/Canadian Glatiramer Acetate Study Group,” Annals of Neurology, vol. 49, no. 3, pp. 290–297, 2001. View at Publisher · View at Google Scholar · View at Scopus
  41. C. Ford, A. D. Goodman, K. Johnson et al., “Continuous long-term immunomodulatory therapy in relapsing multiple sclerosis: Results from the 15-year analysis of the US prospective open-label study of glatiramer acetate,” Multiple Sclerosis Journal, vol. 16, no. 3, pp. 342–350, 2010. View at Publisher · View at Google Scholar · View at Scopus
  42. C. Ford and Ladkani D., “Twenty years of continuous treatment of multiple sclerosis with glatiramer acetate 20 mg daily: Long-term clinical results of the US open-label extension study,” in Proceedings of the 29th Congress of the European Committee for Treatment and Research in Multiple Sclerosis and 18th Annual Conference of Rehabilitation in Multiple Sclerosis, Copenhagen, Denmark, October 2013.
  43. J. S. Wolinsky, G. Comi, M. Filippi, D. Ladkani, S. Kadosh, and G. Shifroni, “Copaxone’s effect on MRI-monitored disease in relapsing MS is reproducible and sustained,” Neurology, vol. 59, no. 8, pp. 1284–1286, 2002. View at Publisher · View at Google Scholar · View at Scopus
  44. M. Rovaris, G. Comi, M. A. Rocca et al., “Long-term follow-up of patients treated with glatiramer acetate: A multicentre, multinational extension of the European/Canadian double-blind, placebo-controlled, MRI-monitored trial,” Multiple Sclerosis Journal, vol. 13, no. 4, pp. 502–508, 2007. View at Publisher · View at Google Scholar
  45. O. Khan, F. Bao, M. Shah et al., “Effect of disease-modifying therapies on brain volume in relapsing-remitting multiple sclerosis: Results of a five-year brain MRI study,” Journal of the Neurological Sciences, vol. 312, no. 1-2, pp. 7–12, 2012. View at Publisher · View at Google Scholar · View at Scopus
  46. N. Bergvall, C. Makin, R. Lahoz et al., “Comparative effectiveness of fingolimod versus interferons or glatiramer acetate for relapse rates in multiple sclerosis: A retrospective US claims database analysis,” Current Medical Research and Opinion, vol. 29, no. 12, pp. 1647–1656, 2013. View at Publisher · View at Google Scholar · View at Scopus
  47. C. Gobbi, C. Zecca, M. Linnebank et al., “Swiss analysis of multiple sclerosis: A multicenter, non-interventional, retrospective cohort study of disease-modifying therapies,” European Neurology, vol. 70, no. 1-2, pp. 35–41, 2013. View at Publisher · View at Google Scholar · View at Scopus
  48. C. Arnal-García, M. del Campo Amigo-Jorrin, A. M. López-Real et al., “Long-term effectiveness of glatiramer acetate in clinical practice conditions,” Journal of Clinical Neuroscience, vol. 21, no. 12, pp. 2212–2218, 2014. View at Publisher · View at Google Scholar · View at Scopus
  49. T. Kalincik, V. Jokubaitis, G. Izquierdo, P. Duquette, M. Girard, and P. Grammond, “Comparative effectiveness of glatiramer acetate and interferon beta formulations in relapsing-remitting multiple sclerosis,” Multiple Sclerosis Journal, vol. 21, pp. 1159–1171, 2015. View at Google Scholar
  50. L. La Mantia, L. M. Munari, and R. Lovati, “Glatiramer acetate for multiple sclerosis,” Cochrane Database of Systematic Reviews, vol. 12, no. 5, Article ID CD004678, 2010. View at Publisher · View at Google Scholar · View at Scopus
  51. D. D. Mikol, F. Barkhof, P. Chang et al., “Comparison of subcutaneous interferon beta-1a with glatiramer acetate in patients with relapsing multiple sclerosis (the REbif vs Glatiramer Acetate in Relapsing MS Disease [REGARD] study): A multicentre, randomised, parallel, open-label trial,” The Lancet Neurology, vol. 7, no. 10, pp. 903–914, 2008. View at Publisher · View at Google Scholar · View at Scopus
  52. D. Cadavid, L. J. Wolansky, J. Skurnick et al., “Efficacy of treatment of MS with IFNβ-1b or glatiramer acetate by monthly brain MRI in the BECOME study,” Neurology, vol. 72, no. 23, pp. 1976–1983, 2009. View at Publisher · View at Google Scholar · View at Scopus
  53. P. O’Connor, M. Filippi, B. Arnason et al., “250 μg or 500 μg interferon beta-1b versus 20 mg glatiramer acetate in relapsing-remitting multiple sclerosis: A prospective, randomised, multicentre study,” The Lancet Neurology, vol. 8, no. 10, pp. 889–897, 2009. View at Publisher · View at Google Scholar
  54. R. J. Fox, D. H. Miller, J. T. Phillips et al., “Placebo-controlled phase 3 study of oral BG-12 or glatiramer in multiple sclerosis,” The New England Journal of Medicine, vol. 367, pp. 1087–1097, 2012. View at Google Scholar
  55. F. D. Lublin, S. S. Cofield, G. R. Cutter et al., “Randomized study combining interferon and glatiramer acetate in multiple sclerosis,” Annals of Neurology, vol. 73, no. 3, pp. 327–340, 2013. View at Publisher · View at Google Scholar · View at Scopus
  56. F. D. Lublin, S. S. Cofield, G. R. Cutter et al., “Long-term follow-up of a randomized study of combination interferon and glatiramer acetate in multiple sclerosis: Efficacy and safety results up to 7 years,” Multiple Sclerosis and Related Disorders, vol. 18, pp. 95–102, 2017. View at Publisher · View at Google Scholar · View at Scopus
  57. K. Tolley, M. Hutchinson, X. You et al., “A network meta-analysis of efficacy and evaluation of safety of subcutaneous pegylated interferon beta-1a versus other injectable therapies for the treatment of relapsing-remitting multiple sclerosis,” PLoS ONE, vol. 10, no. 6, p. e0127960, 2015. View at Google Scholar · View at Scopus
  58. O. Khan, P. Rieckmann, A. Boyko, K. Selmaj, and R. Zivadinov, “Three times weekly glatiramer acetate in relapsing-remitting multiple sclerosis,” Annals of Neurology, vol. 73, no. 6, pp. 705–713, 2013. View at Publisher · View at Google Scholar · View at Scopus
  59. J. S. Wolinsky, T. E. Borresen, D. W. Dietrich et al., “GLACIER: An open-label, randomized, multicenter study to assess the safety and tolerability of glatiramer acetate 40 mg three-times weekly versus 20 mg daily in patients with relapsing-remitting multiple sclerosis,” Multiple Sclerosis and Related Disorders, vol. 4, no. 4, pp. 370–376, 2015. View at Publisher · View at Google Scholar · View at Scopus
  60. T. Ziemssen, N. Ashtamker, S. Rubinchick, V. Knappertz, and G. Comi, “Long-term safety and tolerability of glatiramer acetate 20 mg/ml in the treatment of relapsing forms of multiple sclerosis,” Expert Opinion on Drug Safety, vol. 16, no. 2, pp. 247–255, 2017. View at Publisher · View at Google Scholar · View at Scopus
  61. T. Ziemssen, O. Neuhaus, and R. Hohlfeld, “Risk-benefit assessment of glatiramer acetate in multiple sclerosis,” Drug Safety, vol. 24, no. 13, pp. 979–990, 2001. View at Publisher · View at Google Scholar · View at Scopus
  62. D. M. Balak, G. J. Hengstman, A. Çakmak, and H. B. Thio, “Cutaneous adverse events associated with disease-modifying treatment in multiple sclerosis: A systematic review,” Multiple Sclerosis Journal, vol. 18, no. 12, pp. 1705–1717, 2012. View at Publisher · View at Google Scholar · View at Scopus
  63. J. S. Wolinsky, P. A. Narayana, and K. P. Johnson, “United States open-label glatiramer acetate extension trial for relapsing multiple sclerosis: MRI and clinical correlates. Multiple Sclerosis Study Group and the MRI Analysis Center,” Multiple Sclerosis Journal, vol. 7, no. 1, pp. 33–41, 2001. View at Publisher · View at Google Scholar
  64. M. P. Sormani, M. Rovaris, P. Valsasina, J. S. Wolinsky, G. Comi, and M. Filippi, “Measurement error of two different techniques for brain atrophy assessment in multiple sclerosis,” Neurology, vol. 62, no. 8, pp. 1432–1434, 2004. View at Publisher · View at Google Scholar · View at Scopus
  65. O. Khan, Y. Shen, F. Bao et al., “Long-term study of brain 1H-MRS study in multiple sclerosis: Effect of glatiramer acetate therapy on axonal metabolic function and feasibility of long-term 1H-MRS monitoring in multiple sclerosis,” Journal of Neuroimaging, vol. 18, no. 3, pp. 314–319, 2008. View at Publisher · View at Google Scholar · View at Scopus
  66. M. Filippi, M. Rovaris, M. A. Rocca, M. P. Sormani, J. S. Wolinsky, and G. Comi, “Glatiramer acetate reduces the proportion of new MS lesions evolving into “black holes”,” Neurology, vol. 57, no. 4, pp. 731–733, 2001. View at Publisher · View at Google Scholar · View at Scopus
  67. C. C. Ford, K. P. Johnson, R. P. Lisak, H. S. Panitch, G. Shifronis, and J. S. Wolinsky, “A prospective open-label study of glatiramer acetate: Over a decade of continuous use in multiple sclerosis patients,” Multiple Sclerosis Journal, vol. 12, no. 3, pp. 309–320, 2006. View at Publisher · View at Google Scholar
  68. L. La Mantia, C. Di Pietrantonj, M. Rovaris et al., “Interferons-beta versus glatiramer acetate for relapsing-remitting multiple sclerosis,” Cochrane Database of Systematic Reviews, vol. 11, Article ID CD009333, 2016. View at Publisher · View at Google Scholar
  69. C. Caon, M. Din, W. Ching, A. Tselis, R. Lisak, and O. Khan, “Clinical course after change of immunomodulating therapy in relapsing-remitting multiple sclerosis,” European Journal of Neurology, vol. 13, no. 5, pp. 471–474, 2006. View at Publisher · View at Google Scholar · View at Scopus
  70. H. L. Zwibel, “Glatiramer acetate in treatment-naive and prior interferon-beta-1b-treated multiple sclerosis patients,” Acta Neurologica Scandinavica, vol. 113, pp. 378–386, 2006. View at Google Scholar
  71. T. Ziemssen, O. A. Bajenaru, A. Carrá et al., “A 2-year observational study of patients with relapsing-remitting multiple sclerosis converting to glatiramer acetate from other disease-modifying therapies: The COPTIMIZE trial,” Journal of Neurology, vol. 261, no. 11, pp. 2101–2111, 2014. View at Publisher · View at Google Scholar · View at Scopus
  72. J. Meca-Lallana, L. Hernández, A. B. Caminero et al., “Fatigue improvement after switching multiple sclerosis treatment from interferon-β to glatiramer acetate in clinical practice,” European Neurology, vol. 76, no. 1-2, pp. 40–47, 2016. View at Publisher · View at Google Scholar · View at Scopus
  73. A. Carrá, P. Onaha, G. Luetic et al., “Therapeutic outcome 3 years after switching of immunomodulatory therapies in patients with relapsing-remitting multiple sclerosis in Argentina,” European Journal of Neurology, vol. 15, no. 4, pp. 386–393, 2008. View at Publisher · View at Google Scholar · View at Scopus
  74. J. Havla, L. A. Gerdes, I. Meinl et al., “De-escalation from natalizumab in multiple sclerosis: Recurrence of disease activity despite switching to glatiramer acetate,” Journal of Neurology, vol. 258, no. 9, pp. 1665–1669, 2011. View at Publisher · View at Google Scholar · View at Scopus
  75. R. J. Fox, B. A. Cree, J. De Sèze et al., “MS disease activity in RESTORE: A randomized 24-week natalizumab treatment interruption study,” Neurology, vol. 82, no. 17, pp. 1491–1498, 2014. View at Publisher · View at Google Scholar · View at Scopus
  76. S. Rossi, C. Motta, V. Studer et al., “Effect of glatiramer acetate on disease reactivation in MS patients discontinuing natalizumab,” European Journal of Neurology, vol. 20, no. 1, pp. 87–94, 2013. View at Publisher · View at Google Scholar · View at Scopus
  77. R. Villaverde-González, J. Gracia Gil, A. Pérez Sempere et al., “Observational study of switching from natalizumab to immunomodulatory drugs,” European Neurology, vol. 77, no. 3-4, pp. 130–136, 2017. View at Publisher · View at Google Scholar · View at Scopus
  78. N. Molnarfi, T. Prod’homme, U. Schulze-Topphoff et al., “Glatiramer acetate treatment negatively regulates type I interferon signaling,” Neurology Neuroimmunology & Neuroinflammation, vol. 2, no. 6, p. e179, 2015. View at Google Scholar · View at Scopus
  79. A. D. Goodman, H. Rossman, A. Bar-Or et al., “GLANCE: Results of a phase 2, randomized, double-blind, placebo-controlled study,” Neurology, vol. 72, no. 9, pp. 806–812, 2009. View at Publisher · View at Google Scholar · View at Scopus
  80. M. S. Freedman, J. S. Wolinsky, P. Truffinet et al., “A randomized trial of teriflunomide added to glatiramer acetate in relapsing multiple sclerosis,” Multiple Sclerosis Journal—Experimental, Translational and Clinical, vol. 1, Article ID 205521731561868, 2015. View at Publisher · View at Google Scholar
  81. L. M. Metz, D. Li, A. Traboulsee et al., “Glatiramer acetate in combination with minocycline in patients with relapsing–remitting multiple sclerosis: Results of a Canadian, multicenter, double-blind, placebo-controlled trial,” Multiple Sclerosis Journal, vol. 15, no. 10, pp. 1183–1194, 2009. View at Publisher · View at Google Scholar
  82. N. De Stefano, M. Filippi, and C. Hawkins, “Short-term combination of glatiramer acetate with i.v. steroid treatment preceding treatment with GA alone assessed by MRI-disease activity in patients with relapsing-remitting multiple sclerosis,” Journal of the Neurological Sciences, vol. 266, no. 1-2, pp. 44–50, 2008. View at Publisher · View at Google Scholar · View at Scopus
  83. S. J. Khoury, B. C. Healy, P. Kivisäkk et al., “A randomized controlled double-masked trial of albuterol add-on therapy in patients with multiple sclerosis,” Archives of Neurology, vol. 67, no. 9, pp. 1055–1061, 2010. View at Publisher · View at Google Scholar · View at Scopus
  84. R. R. Voskuhl, H. Wang, T. C. Wu et al., “Estriol combined with glatiramer acetate for women with relapsing-remitting multiple sclerosis: A randomised, placebo-controlled, phase 2 trial,” The Lancet Neurology, vol. 15, no. 1, pp. 35–46, 2016. View at Publisher · View at Google Scholar · View at Scopus
  85. S. Ozakbas, B. P. Cinar, G. Kosehasanoğullari, T. Kahraman, D. Oz, and B. B. Kursun, “Monthly methylprednisolone in combination with interferon beta or glatiramer acetate for relapsing-remitting multiple sclerosis: A multicentre, single-blind, prospective trial,” Clinical Neurology and Neurosurgery, vol. 160, pp. 69–72, 2017. View at Publisher · View at Google Scholar · View at Scopus
  86. L. M. Metz, S. B. Patten, C. J. Archibald et al., “The effect of immunomodulatory treatment on multiple sclerosis fatigue,” Journal of Neurology, Neurosurgery, and Psychiatry, vol. 75, pp. 1045–1047, 2004. View at Publisher · View at Google Scholar
  87. O. Hadjimichael, T. Vollmer, M. Oleen-Burkey, and North American Research Committee on Multiple Sclerosis, “Fatigue characteristics in multiple sclerosis: The North American Research Committee on Multiple Sclerosis (NARCOMS) survey,” Health and Quality of Life Outcomes, vol. 6, p. 100, 2008. View at Publisher · View at Google Scholar · View at Scopus
  88. T. Ziemssen, P. Calabrese, I.-K. Penner, and R. Apfel, “QualiCOP: Real-world effectiveness, tolerability, and quality of life in patients with relapsing-remitting multiple sclerosis treated with glatiramer acetate, treatment-naive patients, and previously treated patients,” Journal of Neurology, vol. 263, no. 4, pp. 784–791, 2016. View at Publisher · View at Google Scholar · View at Scopus
  89. T. Ziemssen, U. Faude, and D. Fendji, “COPAXONE® active registry - documentation of efficacy, tolerability and quality of life in outpatients with relapsing remitting multiple sclerosis (RRMS) treated with glatiramer acetate,” in Proceedings of the 32nd Congress of the European Committee for Treatment and Research in Multiple Sclerosis and 21st Annual Conference of Rehabilitation in MS, London, UK, Abstract no. P1218, 2016.
  90. P. J. Jongen, D. Lehnick, E. Sanders et al., “Health-related quality of life in relapsing remitting multiple sclerosis patients during treatment with glatiramer acetate: A prospective, observational, international, multi-centre study,” Health and Quality of Life Outcomes, vol. 8, p. 133, 2010. View at Google Scholar · View at Scopus
  91. P. J. Jongen, D. Lehnick, J. Koeman et al., “Fatigue and health-related quality of life in relapsing-remitting multiple sclerosis after 2 years glatiramer acetate treatment are predicted by changes at 6 months: An observational multi-center study,” Journal of Neurology, vol. 261, no. 8, pp. 1469–1476, 2014. View at Publisher · View at Google Scholar · View at Scopus
  92. G. Giovannoni, P. Brex, M. Sumra, E. Walters, and K. Schmierer, “Glatiramer acetate slows disability progression results from a 6-year analysis of the UK Risk Sharing Scheme,” in Proceedings of the 31st Congress of the European Committee for Treatment and Research in Multiple Sclerosis, Barcelona, Spain, Abstract no. P1517, 2015.
  93. M. J. Lage, J. Castelli-Haley, and M. A. Oleen-Burkey, “Effect of immunomodulatory therapy and other factors on employment loss time in multiple sclerosis,” Work, vol. 27, no. 2, pp. 143–151, 2006. View at Google Scholar · View at Scopus
  94. T. Ziemssen, J. Hoffman, R. Apfel, and S. Kern, “Effects of glatiramer acetate on fatigue and days of absence from work in first-time treated relapsing-remitting multiple sclerosis,” Health and Quality of Life Outcomes, vol. 6, p. 67, 2008. View at Publisher · View at Google Scholar · View at Scopus
  95. Y. D. Fragoso, A. Finkelsztejn, D. R. Kaimen-Maciel et al., “Long-term use of glatiramer acetate by 11 pregnant women with multiple sclerosis: A retrospective, multicentre case series,” CNS Drugs, vol. 24, no. 11, pp. 969–976, 2010. View at Publisher · View at Google Scholar · View at Scopus
  96. M. Giannini, E. Portaccio, A. Ghezzi et al., “Pregnancy and fetal outcomes after glatiramer acetate exposure in patients with multiple sclerosis: A prospective observational multicentric study,” BMC Neurology, vol. 12, article 124, 2012. View at Publisher · View at Google Scholar · View at Scopus
  97. K. Hellwig, A. Haghikia, M. Rockhoff, and R. Gold, “Multiple sclerosis and pregnancy: Experience from a nationwide database in Germany,” Therapeutic Advances in Neurological Disorders, vol. 5, no. 5, pp. 247–253, 2012. View at Publisher · View at Google Scholar · View at Scopus
  98. S. Herbstritt, A. Langer-Gould, M. Rockhoff et al., “Glatiramer acetate during early pregnancy: A prospective cohort study,” Multiple Sclerosis Journal, vol. 22, no. 6, pp. 810–816, 2016. View at Publisher · View at Google Scholar
  99. H. J. Salminen, H. Leggett, and M. Boggild, “Glatiramer acetate exposure in pregnancy: Preliminary safety and birth outcomes,” Journal of Neurology, vol. 257, no. 12, pp. 2020–2023, 2010. View at Publisher · View at Google Scholar · View at Scopus
  100. C. Weber-Schoendorfer and C. Schaefer, “Multiple sclerosis, immunomodulators, and pregnancy outcome: A prospective observational study,” Multiple Sclerosis Journal, vol. 15, no. 9, pp. 1037–1042, 2009. View at Publisher · View at Google Scholar · View at Scopus
  101. O. Neudorfer, P. Baruch, S. Pery, N. Ashtamker, S. Kolodny, and N. Gavrielov, “Effect of exposure to branded glatiramer acetate during pregnancy on rates of pregnancy loss,” in Proceedings of the 32nd Congress of the European Committee for Treatment and Research in Multiple Sclerosis and 21st Annual Conference of Rehabilitation in MS, London, UK, Abstract no. P1226, 2016.
  102. M. Sandberg-Wollheim, O. Neudorfer, A. Grinspan et al., “Pregnancy outcomes from the branded glatiramer acetate pregnancy database,” International Journal of MS Care, vol. 20, no. 1, pp. 9–14, 2018. View at Publisher · View at Google Scholar · View at Scopus
  103. K. Hellwig, O. Neudorfer, S. Melamed-Gal, and P. Baruch, “Pregnancy outcomes in patients with multiple sclerosis and exposure to branded glatiramer acetate during all three trimesters,” in Proceedings of the 7th Joint Meeting of European Committee for Treatment and Research in Multiple Sclerosis and Americas Committee for Treatment and Research in Multiple Sclerosis, Paris, France, Abstract no. P765, 2017.
  104. Teva Pharmaceuticals Ltd., “Copaxone 20 mg/ml, solution for injection, pre-filled syringe,” 2017, https://www.medicines.org.uk/emc/medicine/17516.
  105. I. Tramacere, C. Del Giovane, G. Salanti, R. D’Amico, and G. Filippini, “Immunomodulators and immunosuppressants for relapsing-remitting multiple sclerosis: A network meta-analysis,” Cochrane Database of Systematic Reviews, vol. 2015, no. 9, Article ID CD011381, 2015. View at Google Scholar · View at Scopus
  106. S. Inusah, M. P. Sormani, S. S. Cofield et al., “Assessing changes in relapse rates in multiple sclerosis,” Multiple Sclerosis Journal, vol. 16, pp. 1414–1421, 2010. View at Google Scholar
  107. Biogen Inc. “AVONEX (interferon beta-1a) injection, for intramuscular injection,” 2016, https://www.avonex.com/content/dam/commercial/multiple-sclerosis/avonex/pat/en_us/pdf/Avonex%20US%20%20Prescribing%20Information.pdf.
  108. PRISMS (Prevention of Relapses and Disability by Interferon beta-1a Subcutaneously in Multiple Sclerosis) Study Group, “Randomised double-blind placebo-controlled study of interferon beta-1a in relapsing/remitting multiple sclerosis,” The Lancet, vol. 352, pp. 1498–1504, 1998, erratum in: Lancet, vol. 353, p. 678, 1999. View at Publisher · View at Google Scholar
  109. IFNB Multiple Sclerosis Study Group, “Interferon beta-1b is effective in relapsing-remitting multiple sclerosis. I: clinical results of a multicenter, randomized, double-blind, placebo-controlled trial,” Neurology, vol. 43, pp. 655–661, 1993. View at Publisher · View at Google Scholar · View at Scopus
  110. P. A. Calabresi, B. C. Kieseier, D. L. Arnold et al., “Pegylated interferon β-1a for relapsing-remitting multiple sclerosis (ADVANCE): A randomised, phase 3, double-blind study,” The Lancet Neurology, vol. 13, no. 7, pp. 657–665, 2014. View at Publisher · View at Google Scholar · View at Scopus
  111. D. Mendes, C. Alves, and F. Batel-Marques, “Benefit-risk of therapies for relapsing-remitting multiple sclerosis: Testing the number needed to treat to benefit (NNTB), number needed to treat to harm (NNTH) and the likelihood to be helped or harmed (LHH): A systematic review and meta-analysis,” CNS Drugs, vol. 30, no. 10, pp. 909–929, 2016. View at Publisher · View at Google Scholar · View at Scopus
  112. EMD Serono, Inc. “NOVANTRONE® MITOXANTRONE for injection concentrate,” 2008, https://www.accessdata.fda.gov/drugsatfda_docs/label/2009/019297s030s031lbl.pdf (Accessed: Oct 26, 2017).
  113. Novartis AG, “GILENYA (fingolimod) capsules, for oral use,” 2016, https://www.pharma.us.novartis.com/sites/www.pharma.us.novartis.com/files/gilenya.pdf.
  114. Biogen Inc., “TYSABRI (natalizumab) injection, for intravenous use,” 2017, https://www.tysabri.com/content/dam/commercial/multiple-sclerosis/tysabri/pat/en_us/pdfs/tysabri_prescribing_information.pdf.
  115. Genzyme Corporation, “LEMTRADA (alemtuzumab) injection, for intravenous use,” 2017, http://products.sanofi.us/Lemtrada/Lemtrada.pdf.
  116. Genentech, Inc., “OCREVUS™ (ocrelizumab) injection, for intravenous use,” 2017, https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/761053lbl.pdf.
  117. R. Haase, J. S. Kullmann, and T. Ziemssen, “Therapy satisfaction and adherence in patients with relapsing-remitting multiple sclerosis: The THEPA-MS survey,” Therapeutic Advances in Neurological Disorders, vol. 9, no. 4, pp. 25–63, 2016. View at Publisher · View at Google Scholar · View at Scopus
  118. J. M. Garcia-Dominguez, D. Muñoz, M. Comellas, I. Gonzalbo, L. Lizán, and C. Polanco Sánchez, “Patient preferences for treatment of multiple sclerosis with disease-modifying therapies: A discrete choice experiment,” Patient Preference and Adherence, vol. 10, pp. 1945–1956, 2016. View at Publisher · View at Google Scholar · View at Scopus
  119. Biogen Inc. “TECFIDERA® (dimethyl fumarate) delayed-release capsules, for oral use,” 2017, https://www.tecfidera.com/content/dam/commercial/multiple-sclerosis/tecfidera/pat/en_us/pdf/full-prescribing-info.pdf.
  120. L. Wilson, A. Loucks, C. Bui et al., “Patient centered decision making: Use of conjoint analysis to determine risk-benefit trade-offs for preference sensitive treatment choices,” Journal of the Neurological Sciences, vol. 344, no. 1-2, pp. 80–87, 2014. View at Publisher · View at Google Scholar · View at Scopus
  121. P. Wicks, D. Brandes, J. Park, D. Liakhovitski, T. Koudinova, and R. Sasane, “Preferred features of oral treatments and predictors of non-adherence: Two web-based choice experiments in multiple sclerosis patients,” Interactive Journal of Medical Research, vol. 4, no. 1, p. e6, 2015. View at Publisher · View at Google Scholar
  122. D. Ferraro, V. Camera, E. Baldi et al., “First-line disease-modifying drugs in relapsing–remitting multiple sclerosis: An Italian real-life multicenter study on persistence,” Current Medical Research and Opinion, vol. 34, no. 10, pp. 1803–1807, 2018. View at Publisher · View at Google Scholar
  123. S. Zhornitsky, J. Greenfield, M. W. Koch et al., “Long-term persistence with injectable therapy in relapsing-remitting multiple sclerosis: An 18-year observational cohort study,” PLoS ONE, vol. 10, no. 4, p. e0123824, 2015. View at Publisher · View at Google Scholar
  124. R. Halpern, R. Wolbeck, C. Blauer-Peterson, Y. Wu, and S. Gandhi, “Adherence to glatiramer acetate 40 mg versus oral disease-modifying therapies for multiple sclerosis,” Value in Health, vol. 18, no. 7, p. A766, 2015. View at Publisher · View at Google Scholar
  125. E. Couto, V. Hamidi, T. Ringerike, J. Odgaard-Jensen, I. Harboe, and M. Klemp, “Medicines used for multiple sclerosis—A health technology assessment,” Norwegian Institute of Public Health, Oslo, 2016, https://www.ncbi.nlm.nih.gov/pubmedhealth/PMH0098781/pdf/PubMedHealth_PMH0098781.pdf.
  126. J. L. Jones, D. J. Scheidt, R. S. Kaushal, and C. A. Carroll, “Assessing the role of patient support services on adherence rates in patients using glatiramer acetate for relapsing-remitting multiple sclerosis,” Journal of Medical Economics, vol. 16, no. 2, pp. 213–220, 2013. View at Publisher · View at Google Scholar · View at Scopus
  127. M. Freidel, S. Ortler, A. Fuchs, S. Seibert, and K. Schuh, “Acceptance of the Extracare Program by beta interferon-treated patients with multiple sclerosis: Results of the EXPLORE study,” Journal of Neuroscience Nursing, vol. 47, no. 1, pp. E31–E39, 2015. View at Publisher · View at Google Scholar · View at Scopus
  128. Genzyme Corporation, “AUBAGIO® (teriflunomide) tablets, for oral use,” 2016, http://products.sanofi.us/aubagio/aubagio.pdf.
  129. S. E. Hatcher, E. Waubant, B. Nourbakhsh, E. Crabtree-Hartman, and J. S. Graves, “Rebound syndrome in patients with multiple sclerosis after cessation of fingolimod treatment,” JAMA Neurology, vol. 73, no. 7, pp. 790–794, 2016. View at Publisher · View at Google Scholar
  130. M. Rasenack and T. Derfuss, “Disease activity return after natalizumab cessation in multiple sclerosis,” Expert Review of Neurotherapeutics, vol. 16, no. 5, pp. 587–594, 2016. View at Publisher · View at Google Scholar · View at Scopus